第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果

2019-02-27 不详网络

强生公司近日宣布，将于3月6日至9日在丹麦哥本哈根举行的第14届欧洲克罗恩病和结肠炎组织（ECCO）大会上公布多项临床试验的最新数据。重点包括III期UNIFI研究的最新数据，UNIFI研究了评估STELARA®（ustekinumab）维持治疗对中重度溃疡性结肠炎（UC）患者的有效性和安全性。

强生公司近日宣布，将于3月6日至9日在丹麦哥本哈根举行的第14届欧洲克罗恩病和结肠炎组织（ECCO）大会上公布多项临床试验的最新数据。重点包括III期UNIFI研究的最新数据，UNIFI研究了评估STELARA®（ustekinumab）维持治疗对中重度溃疡性结肠炎（UC）患者的有效性和安全性。

溃疡性结肠炎（ulcerative colitis，UC），也称非特异性溃疡性结肠炎，是一种会导致结肠与直肠发炎与溃疡的慢性疾病。其发作时的主要症状包括腹痛与伴有血便的腹泻，体重减轻、发热以及贫血的症状也有可能在溃疡性结肠炎发作时出现。通常其症状发生的进程缓慢，且会轻重不一，其症状表现常间歇出现，两次发作中间常伴随有一段无症状期。溃疡性结肠炎的并发症可能包括巨结肠症或眼部、关节或肝脏的炎症，以及结肠癌。

原始出处：

http://www.firstwordpharma.com/node/1626666#axzz5gd5Pbuy9

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1898501, encodeId=6686189850115, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Jul 15 20:02:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954218, encodeId=bd13195421836, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 21 04:02:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984743, encodeId=7d741984e4304, content=<a href='/topic/show?id=c52a501e787' target=_blank style='color:#2F92EE;'>#强生公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50177, encryptionId=c52a501e787, topicName=强生公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun May 12 04:02:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361954, encodeId=759636195479, content=希望有进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/8156a1c5a9d140018d6c82cf25350480/e461c2388df94780957013843309d3b2.jpg, createdBy=db4d2300385, createdName=122060e9m53暂无昵称, createdTime=Mon Mar 04 10:29:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271689, encodeId=cd9112e168976, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339166, encodeId=78a5133916645, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
2019-07-15 xiongliangxl

#研究成果#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1898501, encodeId=6686189850115, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Jul 15 20:02:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954218, encodeId=bd13195421836, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 21 04:02:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984743, encodeId=7d741984e4304, content=<a href='/topic/show?id=c52a501e787' target=_blank style='color:#2F92EE;'>#强生公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50177, encryptionId=c52a501e787, topicName=强生公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun May 12 04:02:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361954, encodeId=759636195479, content=希望有进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/8156a1c5a9d140018d6c82cf25350480/e461c2388df94780957013843309d3b2.jpg, createdBy=db4d2300385, createdName=122060e9m53暂无昵称, createdTime=Mon Mar 04 10:29:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271689, encodeId=cd9112e168976, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339166, encodeId=78a5133916645, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
2019-06-21 仁医06

#ECC#

84 0
[GetPortalCommentsPageByObjectIdResponse(id=1898501, encodeId=6686189850115, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Jul 15 20:02:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954218, encodeId=bd13195421836, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 21 04:02:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984743, encodeId=7d741984e4304, content=<a href='/topic/show?id=c52a501e787' target=_blank style='color:#2F92EE;'>#强生公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50177, encryptionId=c52a501e787, topicName=强生公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun May 12 04:02:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361954, encodeId=759636195479, content=希望有进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/8156a1c5a9d140018d6c82cf25350480/e461c2388df94780957013843309d3b2.jpg, createdBy=db4d2300385, createdName=122060e9m53暂无昵称, createdTime=Mon Mar 04 10:29:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271689, encodeId=cd9112e168976, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339166, encodeId=78a5133916645, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
2019-05-12 ms3153534357578991

#强生公司#

81 0
[GetPortalCommentsPageByObjectIdResponse(id=1898501, encodeId=6686189850115, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Jul 15 20:02:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954218, encodeId=bd13195421836, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 21 04:02:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984743, encodeId=7d741984e4304, content=<a href='/topic/show?id=c52a501e787' target=_blank style='color:#2F92EE;'>#强生公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50177, encryptionId=c52a501e787, topicName=强生公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun May 12 04:02:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361954, encodeId=759636195479, content=希望有进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/8156a1c5a9d140018d6c82cf25350480/e461c2388df94780957013843309d3b2.jpg, createdBy=db4d2300385, createdName=122060e9m53暂无昵称, createdTime=Mon Mar 04 10:29:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271689, encodeId=cd9112e168976, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339166, encodeId=78a5133916645, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
2019-03-04 122060e9m53暂无昵称

希望有进展

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1898501, encodeId=6686189850115, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Jul 15 20:02:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954218, encodeId=bd13195421836, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 21 04:02:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984743, encodeId=7d741984e4304, content=<a href='/topic/show?id=c52a501e787' target=_blank style='color:#2F92EE;'>#强生公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50177, encryptionId=c52a501e787, topicName=强生公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun May 12 04:02:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361954, encodeId=759636195479, content=希望有进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/8156a1c5a9d140018d6c82cf25350480/e461c2388df94780957013843309d3b2.jpg, createdBy=db4d2300385, createdName=122060e9m53暂无昵称, createdTime=Mon Mar 04 10:29:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271689, encodeId=cd9112e168976, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339166, encodeId=78a5133916645, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
2019-03-01 liuyong2980

#强生#

78 0
[GetPortalCommentsPageByObjectIdResponse(id=1898501, encodeId=6686189850115, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Jul 15 20:02:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954218, encodeId=bd13195421836, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 21 04:02:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984743, encodeId=7d741984e4304, content=<a href='/topic/show?id=c52a501e787' target=_blank style='color:#2F92EE;'>#强生公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50177, encryptionId=c52a501e787, topicName=强生公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun May 12 04:02:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361954, encodeId=759636195479, content=希望有进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/8156a1c5a9d140018d6c82cf25350480/e461c2388df94780957013843309d3b2.jpg, createdBy=db4d2300385, createdName=122060e9m53暂无昵称, createdTime=Mon Mar 04 10:29:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271689, encodeId=cd9112e168976, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339166, encodeId=78a5133916645, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Mar 01 09:02:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
2019-03-01 ms9474365431325850

#欧洲#

65 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化

第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果

相关资讯

科室

工具

服务

消化

第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果

相关资讯

2017ECCO精彩看点：吴开春：溃疡性结肠炎（UC）的临床诊断和治疗

2017ECCO精彩看点：冉志华：炎症性肠病（IBD）的慢病管理

2017ECCO精彩看点：钟捷：炎症性肠病（IBD）的个体化治疗新理念

科室

工具

服务